ABVC
ABVC BioPharma, Inc.
There isn't enough reported data to score ABVC yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ABVC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ABVC's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABVC PE Valuation
ABVC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ABVC Forward outlook
There aren't enough analyst estimates for ABVC to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ABVC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$1.38 | +$2.02 |
| Q2 2024 | -$2.18 | +$1.50 |
| Q1 2024 | -$2.77 | +$0.83 |
| Q4 2023 | -$2.97 | +$2.03 |
| Q3 2023 | -$3.40 | +$3.35 |
| Q2 2023 | -$3.68 | +$2.67 |
| Q1 2023 | -$3.60 | +$2.95 |
| Q4 2022 | -$5.00 | +$0.05 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 114% for ABVC versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ABVC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $796K | +104% |
| Q4 2024 | $2K | -9.2% |
| Q3 2024 | $389.3K | +2351% |
| Q2 2024 | $117.1K | +1818% |
| Q1 2024 | $1.2K | -99% |
| Q4 2023 | $2.2K | -100% |
| Q3 2023 | $15.9K | -62% |
| Q2 2023 | $6.1K | -98% |
LLY has the stronger quarterly revenue trend. Revenue is down 779% for ABVC versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -247% | -260 points |
| Q4 2024 | -16997% | +73609 points |
| Q3 2024 | 13% | +13579 points |
| Q2 2024 | -834% | +35078 points |
| Q1 2024 | -285841% | -284355 points |
| Q4 2023 | -90606% | -90074 points |
| Q3 2023 | -13566% | -4775 points |
| Q2 2023 | -35912% | -35257 points |
ABVC's operating margin was −247% last quarter, up 285595 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ABVC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$894.2K | -$354.4K |
| Q2 2025 | -$894.2K | +$119.9K |
| Q1 2025 | -$539.8K | -$66.7K |
| Q1 2024 | -$473.2K | +$1M |
| Q1 2023 | -$1.5M | +$1.6M |
| Q2 2022 | -$3.5M | -$2M |
| Q1 2022 | -$3.1M | -$1.7M |
| Q4 2021 | -$1.8M | +$1.4M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with ABVC at up 29%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ABVC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +598K shares |
| 1 year | +15% | +3.4M shares |
| 3 years | +706% | +23.3M shares |
| 5 years | +992% | +24.2M shares |
| Available history | +1423% | +24.9M shares |
ABVC has 27M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2021 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ABVC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ABVC Net Leverage
ABVC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ABVC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 51.7 | Neutral |
ABVC's weekly RSI is 43 (neutral) and its Stochastic is 52 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ABVC PE vs Healthcare Sector
ABVC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ABVC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 4% below |
| 20 week MA | $1.07 | 10% below |
| 50 week MA | $1.36 | 29% below |
| 100 week MA | $1.60 | 40% below |
| 200 week MA | $2.06 | 53% below |
ABVC is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ABVC on trend strength, trading above more of its moving averages.
ABVC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $52.0 | +1% |
| 2021 | $52.0 | $37.7 | -27% |
| 2022 | $37.7 | $6.90 | -82% |
| 2023 | $6.90 | $1.16 | -83% |
| 2024 | $1.16 | $0.58 | -50% |
| 2025 | $0.58 | $2.43 | +319% |
| 2026 YTD | $2.43 | $0.96 | -60% |
ABVC's yearly returns have swung widely, from +319% in 2025 to −83% in 2023. It's down 60% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ABVC on returns for 2026, with the stronger performance.